ASCO 2025：关键见解和创新（英）
ASCO 2025: Key Insights and Innovations HR+/HER2- Breast Cancer The Phase III SERENA-6 Trial
报告摘要
ASCO 2025: Key Insights and Innovations HR+/HER2- Breast Cancer The Phase III SERENA-6 Trial
报告信息
- 文件全名
- 《ASCO 2025：关键见解和创新（英）-58页.pdf》
- 适合读者
- 核心数据
- ▪ Approximately 70% of breast cancers are ER+/HER2▪ ESR1 mutations activate estrogen receptor (ER) signaling, leading to endocrine resistance
- ▪ ESR1 mutations are rare at diagnosis but emerge in ~40% of patients after progression on
- 核心议题
常见问题
《ASCO 2025：关键见解和创新（英）》主要包含哪些内容?
ASCO 2025: Key Insights and Innovations HR+/HER2- Breast Cancer The Phase III SERENA-6 Trial核心数据:▪ Approximately 70% of breast cancers are ER+/HER2▪ ESR1 mutations activate estrogen receptor (ER) signaling, leading to endocrine resistance;▪ ESR1 mutations are rare at diagnosis but emerge in ~40% of patients after progression on。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 58。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了AI等议题。
继续阅读
查看全部 →